Levothyroxine sodium and Hyperammonaemia - a phase IV clinical study of FDA data

Summary:

Hyperammonaemia is reported as a side effect among people who take Levothyroxine sodium (levothyroxine sodium), especially for people who are female, 60+ old, also take Depakote, and have Bipolar disorder.

The phase IV clinical study analyzes which people have Hyperammonaemia when taking Levothyroxine sodium. It is created by eHealthMe based on reports of 122,907 people who have side effects when taking Levothyroxine sodium from the FDA, and is updated regularly.

What is Levothyroxine sodium?

Levothyroxine sodium has active ingredients of levothyroxine sodium. It is often used in hypothyroidism. eHealthMe is studying from 129,812 Levothyroxine sodium users. Check the latest studies of Levothyroxine sodium.

What is Hyperammonaemia?

Hyperammonaemia is found to be associated with 405 drugs and 559 conditions by eHealthMe. Check the latest studies of Hyperammonaemia.

On Jul, 08, 2026

122,907 people reported to have side effects when taking Levothyroxine sodium.
Among them, 40 people (0.03%) have Hyperammonaemia.

Could Levothyroxine sodium cause Hyperammonaemia?

Among these 40 people:

What is the gender of people who have Hyperammonaemia when taking Levothyroxine sodium? *

female: 67.5 %
male: 32.5 %

What is the age of people who have Hyperammonaemia when taking Levothyroxine sodium? *

What are other drugs people take besides Levothyroxine sodium? *

What are other side effects people have besides Hyperammonaemia? *

Weakness: 10 people, 25.00%
Hepatic Encephalopathy (spectrum of neuropsychiatric abnormalities in patients with liver failure): 8 people, 20.00%
Fatigue (feeling of tiredness): 6 people, 15.00%
Thrombocytopenia (decrease of platelets in blood): 5 people, 12.50%
Gastrointestinal Necrosis (destruction of gastrointestinal organ): 5 people, 12.50%
Fall: 5 people, 12.50%
Dehydration (dryness resulting from the removal of water): 5 people, 12.50%
Renal Impairment (severely reduced kidney function): 5 people, 12.50%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 5 people, 12.50%
Diarrhea: 4 people, 10.00%

What are the existing conditions these people have? *

Bipolar Disorder (mood disorder): 7 people, 17.50%
Hiv Infection: 3 people, 7.50%
Hepatocellular Carcinoma (liver cancer): 3 people, 7.50%
Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 2 people, 5.00%
Drug Exposure During Pregnancy: 2 people, 5.00%
Hepatitis C: 2 people, 5.00%
Mouth Ulcers: 2 people, 5.00%
Mania (a state of abnormally elevated or irritable mood): 1 person, 2.50%
Hepatitis C Antibody Positive: 1 person, 2.50%
Renal Cell Carcinoma (a kidney cancer): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Levothyroxine sodium and have Hyperammonaemia?

- Check whether Hyperammonaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Levothyroxine sodium:

Levothyroxine sodium (129,812 reports)

Hyperammonaemia treatments and more:

Hyperammonaemia (6,053 reports)

Browse all side effects of Levothyroxine sodium:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperammonaemia:

Hyperammonaemia (405 drugs)

Browse all the conditions that are associated with Hyperammonaemia:

Hyperammonaemia (559 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on levothyroxine sodium (the active ingredients of Levothyroxine sodium) and Levothyroxine sodium (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.